The company has not filed an annual or quarterly report since its Q1 FY2023 10-Q, filed May 5, 2023. Its latest SEC filing is a 15-12G from Jun 23, 2023.
10-Q for Q1 FY2023, filed May 5, 2023
The sections below describe the company as of the FY2022 annual report.
Sells veterinary diagnostic laboratory instruments and consumables, imaging equipment, and related software and services to veterinary practitioners.
10-K for FY2022, filed Feb 28, 2023We sell, manufacture, market and support diagnostic and specialty products and solutions for veterinary practitioners. Our portfolio…View ↗
We offer a portfolio of veterinary POC (stationary and portable) laboratory diagnostic instruments for testing blood and other biological…View ↗
Digital Radiography. We sell equipment, including digital radiography detectors and related accessories for use in digital radiography…View ↗
Veterinary practices pay outright for most imaging equipment and pharmaceuticals, vaccines and diagnostic products; for many lab instruments, they pay a monthly fee for the testing supplies needed to run them. International veterinary practices also buy software licenses at delivery and pay over time for support and cloud services.
10-K for FY2022, filed Feb 28, 2023We generate revenue through the sale of products, either by outright purchase by our customers or through a subscription agreement whereby…View ↗
With the acquisition of VetZ on January 3, 2022, the Company entered the market for veterinary PIMS. Revenue for the sale of software…View ↗
For outright sales of products, revenue is recognized when control of the promised product or service is transferred to our customers, in…View ↗
Our revenue under subscription agreements relates to operating-type lease ("OTL") arrangements or sales-type lease ("STL") arrangements.…View ↗
10-K for FY2022, filed Feb 28, 2023
FY2022 revenue by reportable segment ↗$257.3M
10-K for FY2022, filed Mar 1, 2023
$257.3M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
North America Segment
Mix
10-K for FY2022, filed Feb 28, 2023 |
63%
FY2019: 94%
|
North America Segment, FY2022
$161.8M Sources
|
Mix |
|
International Segment
Mix
10-K for FY2022, filed Feb 28, 2023 |
37%
FY2019: 5.9%
|
International Segment, FY2022
$95.5M Sources
|
Mix |
Veterinary practitioners are the main end customers; Heska sells directly and through third-party veterinary diagnostic laboratories and independent distributors.
10-K for FY2022, filed Feb 28, 2023
No. It lost $19.9M in FY2022.
10-K for FY2022, filed Mar 1, 2023
10-Q for Q1 FY2023, filed May 6, 2023
−$10.1MView ↗
10-Q for Q1 FY2023, filed May 5, 2023
Open tableView ↗
8-K, filed Jun 13, 2023
In connection with the consummation of the Merger, the Company notified representatives of the Nasdaq Stock Market LLC (“NASDAQ”) that the…View ↗
8-K, filed Apr 3, 2023
The Merger Agreement provides that, subject to the terms and conditions set forth therein, at the effective time of the Merger (the…View ↗
Grew. Revenue grew 2.0x in 4 years, from $127.4M in FY2018 to $257.3M in FY2022, about 19% a year.
New software and cytology
Added digital cytology services and veterinary practice-management software through acquisitions, extending the earlier portfolio of laboratory and imaging diagnostics, vaccines, allergy products and single-use tests.
10-K for FY2019, filed Feb 28, 2020 10-K for FY2022, filed Feb 28, 2023We sell veterinary and animal health diagnostic and specialty products. Our offerings include Point of Care diagnostic laboratory…View ↗
We sell, manufacture, market and support diagnostic and specialty products and solutions for veterinary practitioners. Our portfolio…View ↗
In 2021, we: acquired BiEsse A-Laboratorio die Analisi Veterinarie S.r.l. (“BSA”), based in Milan, Italy, which expanded our reference…View ↗
On January 3, 2022, we acquired Veterinärmedizinisches Dienstleistungszentrum (VetZ) GmbH (“VetZ”). VetZ is a European leader in veterinary…View ↗
Competes with IDEXX Laboratories, Zoetis, Boehringer Ingelheim, CEVA Santé Animale, Elanco, Merck Animal Health, Sanofi, Vétoquinol, and Virbac
10-K for FY2022, filed Feb 28, 2023Our market is intensely competitive. Our competitors include animal health companies and major pharmaceutical companies that have animal…View ↗
Loading...
